DNA damage response: A barrier or a path to tumor progression?

Cancer Biology and Therapy

Volumn 9, Issue 3, 2010, Pages 252-254

  Studzinski, George P ^a   Wang, Xuening ^a   Danilenko, Michael ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Apoptosis; ATM ATR; Cancer prevention; Cell cycle control; Checkpoints; DNA damage; Tumorigenesis

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; HISTONE H2AX;

CELL CYCLE ARREST; COLORECTAL CARCINOMA; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; ENZYME ACTIVATION; HUMAN; NOTE; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 77953597702     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.3.10959     Document Type: Note

References (27)

1. Oka K, Tanaka T, Enoki T, Yoshimura K, Ohshima M, Kubo M, et al. DNA damage signaling is activated during cancer progression in human colorectal carcinoma. Cancer Biol Ther 2010; 9:245-51.
2. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 2001;276:42462-7.
3. Falck J, Petrini JH, Williams BR, Lukas J, Bartek J. The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways. Nat Gene 2002; 30:290-4.
4. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3:421-9. (Pubitemid 38340288)
5. Tanaka T, Halicka HD, Huang X, Traganos F, Darzynkiewicz Z. Constitutive histone H2AX phosphorylation and ATM activation, the reporters of DNA damage by endogenous oxidants. Cell Cycle 2006; 5:1940-5.
6. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358:15-6.
7. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-25.
8. 1 arrest and apoptosis. Cancer Res 1994; 54:1169-74.
9. Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, et al. Immediate early upregulation of bax expression by p53 but not TGFbeta1: a paradigm for distinct apoptotic pathways. Oncogene 1994; 9:1791-8. (Pubitemid 24163410)
10. Burns TF, El-Deiry WS. Microarray analysis of p53 target gene expression patterns in the spleen and thymus in response to ionizing radiation. Cancer Biol Ther 2003; 2:431-43.
11. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359:235-7.
12. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008; 135:1079-99.
13. Studzinski GP, Gierthy JF. Selective inhibition of the cell cycle of cultured human diploid fibroblasts by aminonucleoside of puromycin. J Cell Physiol 1973;81:71-83.
14. Gierthy JF, Studzinski GP. Absence of aminonucleoside-sensitive steps in the cell cycle of SV40-transformed human fibroblasts. Cancer Res 1973;33:2673-6.
15. Bruno S, Ardelt B, Skierski JS, Traganos F, Darzynkiewicz Z. Different effects of staurosporine, an inhibitor of protein kinases, on the cell cycle and chromatin structure of normal and leukemic lymphocytes. Cancer Res 1992; 52:470-3.
16. Blagosklonny MV, Darzynkiewicz Z. Cyclotherapy: protection of normal cells and unshielding of cancer cells. Cell Cycle 2002; 1:375-82.
17. Bartek J, Bartkova J, Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 2007; 26:7773-9. (Pubitemid 350242463)
18. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008; 319:1352-5. (Pubitemid 351354863)
19. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434:864-70.
20. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434:907-13.
21. Huang H, Regan KM, Lou Z, Chen J, Tindall DJ. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science 2006;314:294-7.
22. Ljungman M. Targeting the DNA damage response in cancer. Chem Rev 2009; 109:2929-50.
23. Pesakhov S, Khanin M, Studzinski GP, Danilenko M. Distinct combinatorial effects of the plant polyphenols curcumin, carnosic acid and silibinin on proliferation and apoptosis in acute myeloid leukemia cells. Nutr Cancer; In press.
24. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y, et al. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 1997; 387:516-9.
25. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG Jr, Levrero M, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399:806-9.
26. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 1999; 399:814-7.
27. Pietsch EC, Sykes SM, McMahon SB, Murphy ME. The p53 family and programmed cell death. Oncogene 2008; 27:6507-21.